Back to News

Spartan Bioscience Names Nick Noreau as Chief Revenue Officer

April 9th, 2019

Spartan Bioscience today announced that Nick Noreau has been named Chief Revenue Officer. Mr. Noreau will lead revenue growth and market expansion for Spartan’s DNA diagnostic devices and tests.

Mr. Noreau has more than 20 years of global sales experience at technology and healthcare companies. He joins Spartan from Nuance Communications (NASQAD:NUAN), where he served as Regional Vice President of Healthcare Sales. In 2016, Mr. Noreau led an acquisition for Nuance and grew the division’s revenues from $30 million to $72 million in two years. Previously, Mr. Noreau held senior leadership roles at Veritaaq, Taima (acquired by Convergys), and Accentus (acquired by Nuance).

“Nick’s proven ability to scale companies from startup to major revenues will play a key role in Spartan’s continued growth,” said Paul Lem, M.D., CEO of Spartan Bioscience. “He is an excellent addition to our leadership team.”

“Spartan is leading the way to a diagnostics revolution with their portable DNA testing technology and I am excited to build on their incredible momentum as Chief Revenue Officer,” said Mr. Noreau.

For more information about careers at Spartan, please visit http://www.spartanbio.com/about-us/careers/.

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(1) Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. The Spartan Cube, the world’s smallest DNA analyzer, enables unprecedented portability and convenience in applications such as infectious disease, pharmacogenetics, and food and water safety testing. For more information, please visit http://www.spartanbio.com.

  1. Roberts JD et al. (2012). Lancet. 379:1705–11.